RESPILIQ - enteral CO2 absorption for the therapy of hypercapnic lung failure

Introduction

Premature babies and patients with acute lung failure in the intensive care unit or COPD patients at home all suffer from the same potentially fatal condition: hypercapnia, which is an increased level of CO2 in the blood. In Europe alone, there are around 1.8 million people affected by this condition.

Problem Statement

Hypercapnia is one of the major challenges in the therapy of acute lung failure and long-term weaning in ICU, as well as in the outpatient treatment of COPD. This issue has not yet been adequately solved, leading to significant health risks for these patient groups.

Project Goal

Our goal is to revolutionize therapy and significantly improve survival and, above all, the quality of life of these large patient groups suffering from hypercapnia.

Innovative Approach

Instead of tackling the problem via the lungs, RESPILIQ uses the human gut as a respiratory organ. The intestine forms a highly effective exchange membrane for carbon dioxide (CO2).

Mechanism of Action

In the gut, RESPILIQ can bind CO2 from the intestinal fluid and excrete it via natural means. Administered orally or rectally, RESPILIQ initiates a life-saving reduction of pCO2 in the blood.